Faculty

Edward H. Lin, MD

Edward H. Lin, MD

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-830
Seattle, WA 98109-1023


Admin Contact

Assistant to Dr. Lin
206.288.6426
Fax: 206.288.2042

Specialty / Expertise

Gastrointestinal cancers

Research Interests

Colon Cancer Stem Cells

Current Research Projects

BRISK
Sponsor: Bristol-Myers Squibb Company
Role: Principal Investigator
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma.

Training

Dr. Lin received his MD from China Medical University, Shenyang, China. He completed his Internal Medicine Residency at Brown University, Providence, RI. He was a Post-Doctoral Fellow in Hematology/Oncology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Selected Publications

Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-RaJ S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal patterns of fatigue predict pathological response in patients treated with preoperative chemoradiation therapy (CRT) for rectal cancer. Int J Radiat Oncol Bio Phys. 2009;75(3):775-81. (PMID: 19231100)

Tu L, Foltz G, Lin E, Hood L, Qiang T. Targeting stem cells-clinical implications for cancer therapy. Current Stem Cell Research and Therapy. 2009; 4(2):147-53 (PMID: 19442199)

van Cutsem E, Lin E, Bahetta, E, Valle J,  Kohne CH, Hecht RJ,  Moore M,  Germond C, Chen B, Jalava H, Lebwohl D, Laurent D, A randomized, phase III study of FOLFOX4 with PTK787/ZK 222584 or placebo in second-line colorectal cancer patients. JCO. Iin press.

E Van Custem, Lin E, P Bono, Y Humblet, T Jalava, E Masson, A Kay, D Laurent, H Joensuu, Jacque C. A Phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with Irinotecan in Patients (Pts) with metastatic colorectal cancer (CRC). Ann Oncol submitted.

Lin E, et al. Cancer stem cells, endothelial progenitors, and messenchymal stem cells: “seed and soil” theory revisited. Gastrointest Cancer Res. 2008 Jul;2(4):169-74. (PMID: 19259284)

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26(32):5254-60. Epub 2008 Oct 14. (PMID: 18854565)

Lin EH, Hassan M, Li Z, Zhao H, et al. Elevated circulating endothelial progenitor markers CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007;110:534-42. (PMID: 17594720)

Das P, Lin E, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiation Oncol Biol Phys 2006;66:1378-83. Epub 2006 Oct 23. (PMID: 17056196)

Krishnan S, Lin E, Brandon G1, Chandra A, Das P, Delcos M, Janjan N, Crane C. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. AJCO 2006;29(6):562-7. (PMID: 17148992)

Lin E, C Curley S, Crane C, Rodriguez-Bigas M, Feig B, Ayer G, Delcos M, Morris, J, Ross A Brown T, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006;29(3):232-9. (PMID: 16755175)

Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C, Dutta A, Bogaard KR, Abbruzzese JL. Phase II study of Oxaliplatin and Irinotecan in frontline treatment of metastatic colorectal cancer. Cancer. 2006;106(10):2241-6. (PMID: 16598762)

Xiong HQ. Abbruzzese JL. Lin E. Wang L. Zheng L. Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. International Journal of Cancer. 108(2):181-8, 2004. (PMID: 14639600)

Kotani J, Avallone NJ, Lin E, Goshima M, Gandhi K, Lowry SF, Calvano SE. Fas-mediated neutrophil apoptosis and associated A1 protein expression during systemic inflammation are regulated independently of both tumor necrosis factor receptors. Shock. 2003 Mar;19(3):201-7. (PMID: 12630518)

Lin E, Morris J, Moyer G. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park). 2002 Dec;16(12 Suppl No 14):31-7. (PMID: 12520638)

E.H. Lin, X.C. He, Y. Deng, R. Yeung, J. Gu, S. Curley, J. Haug , S. Hamilton, A. Blau, X. Wu, Q. Tian, L. Li. Efficiently targeting cancer stem cells requires tactical activation from their dormant state and subsequent exhaustion. AACR, late breaking abstr 2010.

Lin E. Editor in Chief,  5th edition, Cancer-matrix Manual

Lin E and Mitchell E. Strategy for managing patients with metastatic colorectal cancer. Expert commentary on the management of colorectal cancer. Oncology [2007].

Janjan NA, Lin E, Delclos ME, Crane C, , In: Ajani JA, Curley S, Janjan NA, Lynch PM, eds. Management of Spinal cord metastasis in, Oxford Press. M. D. Anderson Cancer Care Series, vol 3, pp. 299-303. 2007

Lin E. (Editor in chief) 4th edition Cancer Matrix Treatment Books (2006). Published by Advanced Medical Publishing, in an online, CD and pocketbook format. (In press). This new edition features expanded cancer staging information along with ICD9 code, radiation therapy, molecular targeted therapy, expanded cancer matrix algorithms, and key meeting update and targeted therapy, and 5 Minutes hematology consults.

Lin E et al. Key updates from journals and meetings. Cancer Matrix, 4th edition. 2006 by Advanced Medical Publishing.

Last updated: May 2011

Top